A follow-up strategy without radioiodine appeared noninferior to an ablation strategy with radioiodine among patients with low-risk thyroid cancer undergoing thyroidectomy, according to study results in The New England Journal of Medicine.
Postoperative administration of radioiodine is controversial in the treatment setting for patients with low-risk differentiated thyroid cancer undergoing thyroidectomy.
“In patients with pathological tumor-node-metastasis (pTNM) stage I disease, retrospective studies have shown inconsistent results regarding the usefulness of radioiodine administration,”